Identification of Specific Biomarkers and Pathways in the Treatment Response of Infliximab for Inflammatory Bowel Disease: In-Silico Analysis

Abstract excerpt

BACKGROUND: Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract. In biological therapy, infliximab became the first anti-tumor necrosis factor (TNF) agent approved for IBD. Despite this success, infliximab is expensive, often ineffective, and associated with adverse events. Prediction of infliximab resistance would improve overall potential outcomes. Therefore,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Inflammation biomarkers and pathways
• Share to Inflammatory Bowel Disease
• Share to Spondyloarthritis Studies and Treatments